Sanders calls on USPTO to block Gilead patent extension
US presidential candidate Bernie Sanders has called on the US Patent and Trademark Office (USPTO) to block extensions to two Gilead Sciences patents covering HIV prevention drugs including Descovy (tenofovir alafenamide/embicitrane).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
16 December 2019 The US Patent and Trademark Office is coming under increasing pressure to review allegations that Gilead delayed development of its latest HIV drug in order to maximise profits.
7 November 2019 The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.
22 August 2019 Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.